Indian Drug Makers Are Going Local for Ending Their Reliance on China


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴
“India is the largest provider of generic medicines globally but depends on China and other countries for API’s”

India is recognized as the pharmacy of the world for its massive production capacities of both generic drugs and vaccines, India is depending on China for half of its API needs.

Indian pharmaceutical companies are seeking local makers of Active Pharmaceutical Ingredients (API) or trying to produce them in-house to end their dependency on China as relations between the two countries soured after a deadly border clash.

All About API

Active Pharmaceutical Ingredient is any substance or combination of substance used in Finished Pharmaceutical Product intended to furnish Pharmacological Activity or have direct effect in the diagnosis, cure, mitigation, treatment, prevention of disease.

Raw Materials are the Chemical compound that is used as a base to make API. API is not made by only one reaction from raw material but involves several other chemical compounds. These chemical compounds which are in process of becoming API are called Intermediate. The quality of API should be ultrapure to meet the strict quality criteria of medicine. Medicines are made by mixing pharmaceutical excipients and API’s.

Executives of India's Cadila Healthcare, Cipla, Sun Pharmaceutical, and Biocon said, "they are aggressively working on reducing the dependence on the rival country for raw material. Interruption to supplies from China due to Covid 19 pandemic is also one of the reasons.”

Last year during lockdown many of the Indian pharmaceutical companies had to face difficulties in buying ingredients to make important drugs to be sold all over the world.

“Because of the anti-China sentiments, most of the companies are working towards de-risking themselves in terms of making it clear that their supply chain linkages with China are limited,” Gaurav Suchak, supply head of Cadila.

Tags : #medicircle #smitakumar #indianpharma #genericdrugs #API

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026